

Stanford



Carina Mari Aparici

Clinical Professor, Radiology - Rad/Nuclear Medicine

CLINICAL OFFICE (PRIMARY)

- **Nuclear Medicine**
300 Pasteur Dr H2200
MC 5281
Stanford, CA 94305
Tel (650) 723-6855 **Fax** (650) 498-5047

ACADEMIC CONTACT INFORMATION

- **Administrative contact**
Meke Fa'aoso - Administrative Associate
Email mfaaoso@stanford.edu
Tel 650-497-5373

Bio

CLINICAL FOCUS

- Nuclear Medicine

ACADEMIC APPOINTMENTS

- Clinical Professor, Radiology - Rad/Nuclear Medicine

PROFESSIONAL EDUCATION

- Residency: Stanford University Nuclear Medicine Residency (2005) CA
- Board Certification: Nuclear Medicine, American Board of Nuclear Medicine (2005)
- Medical Education: Universitat de Valencia (1992) Spain

Research & Scholarship

CLINICAL TRIALS

- 18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules, Recruiting
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE, Recruiting
- A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer, Not Recruiting
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients, Not Recruiting

Publications

PUBLICATIONS

- **Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report.** *Cureus*
Zhang, V., Tapparra, K., Fisher, G., Aparici, C., Soltys, S. G.
2023; 15 (9): e45327

- **Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer**
Song, H., Sjostrand, K., Duan, H., Ferri, V., Aparici, C., Davidzon, G., Franc, B., Moradi, F., Anand, A., Iagaru, A.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting.** *European journal of nuclear medicine and molecular imaging*
Song, H., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Nguyen, J., Shah, J., Iagaru, A.
2023
- **A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Kunder, C., Mari Aparici, C., Davidzon, G. A., Moradi, F., Sonn, G. A., Iagaru, A.
2022
- **A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Davidzon, G. A., Mari Aparici, C., Kunder, C., Sonn, G., Iagaru, A.
2022
- **A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy**
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Davidzon, G. A., Aparici, C., Thong, A., Sonn, G. A., Kunder, C., Iagaru, A.
SPRINGER.2022: S497-S498
- **Head-to-head Comparison of a Conventional or CZT-based SPECT/CT with a Next Generation Multidetector CZT-based SPECT/CT System**
Duan, H., Ferri, V., Castaneda, P., Visser, T., Luong, K., Davidzon, G. A., Aparici, C., Iagaru, A.
SPRINGER.2022: S263
- **A Pilot Study of Ga-68-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer**
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Sonn, G. A., Kunder, C., Davidzon, G. A., Aparici, C., Moradi, F., Iagaru, A.
SPRINGER.2022: S484
- **Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177Lu-DOTATATE.** *Clinical nuclear medicine*
Somoza, E. A., Duan, H., Shaheen, S., Fischer, G. A., Aparici, C. M.
2022
- **Hong Song, Heying Duan, Caitlyn Harrison, Kip Guja, Negin Hatami, Judy Nguyen, Benjamin Franc, Farshad Moradi, Carina Mari Aparici, Guido Davidzon, Sandy Srinivas and Andrei Iagaru**
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Nguyen, J., Franc, B., Moradi, F., Aparici, C., Davidzon, G., Srinivas, S., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2022
- **Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.** *The oncologist*
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., Mari Aparici, C.
2022
- **Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up** *ONCOLOGIST*
Duan, H., Ferri, V., Fisher, G., Shaheen, S., Davidzon, G., Iagaru, A., Aparici, C.
2022
- **Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience**
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., Nguyen, J., Franc, B. L., Iagaru, A., Aparici, C.
LIPPINCOTT WILLIAMS & WILKINS.2022: E42-E43
- **Response to Letter to Editor re: "Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms".** *Academic radiology*
Lee, H., Nakamoto, R., Moore, S. E., Pantel, A. R., Eads, J. R., Aparici, C. M., Pryma, D. A.
2022

- **Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.** *Nanotheranostics*
Duan, H., Iagaru, A., Aparici, C. M.
1800; 6 (1): 103-117
- **Multi-tracer PET Imaging Using Deep Learning: Applications in Patients with High-Grade Gliomas**
Wardak, M., Hooper, S. M., Schiepers, C., Chen, W., Aparici, C., Davidzon, G. A., Vermesh, O., Cloughesy, T. F., Huang, S., Gambhir, S., Rekić, Adeli, E., Park, S. H., et al
SPRINGER INTERNATIONAL PUBLISHING AG.2022: 24-35
- **Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.** *Academic radiology*
Lee, H., Nakamoto, R., Moore, S. E., Pantel, A. R., Eads, J. R., Aparici, C. M., Pryma, D. A.
2021
- **68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors.** *Translational oncology*
Duan, H., Baratto, L., Hatami, N., Liang, T., Mari Aparici, C., Davidzon, G. A., Iagaru, A.
2021; 15 (1): 101293
- **A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy**
Duan, H., Ghanouni, P., Hatami, N., Davidzon, G. A., Aparici, C., Thong, A., Sonn, G. A., Iagaru, A.
SPRINGER.2021: S205-S206
- **PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES**
Song, H., Nguyen, J., Moradi, F., Aparici, C., Franc, B., Davidzon, G., Iagaru, A.
LIPPINCOTT WILLIAMS & WILKINS.2021: E1177-E1178
- **A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer**
Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G. A., Aparici, C., Thong, A., Sonn, G. A., Iagaru, A.
SPRINGER.2021: S204
- **COMPETE Phase III Trial - Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177-Edotreotide vs. Everolimus in Progressive GEP-NET.**
Wahba, M. M., Strosberg, J., Avram, A., Aparici, C.
AMER ASSOC CANCER RESEARCH.2021
- **Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors.** *Diagnostics (Basel, Switzerland)*
Baratto, L., Torihara, A., Hatami, N., Aparici, C. M., Davidzon, G., Levin, C. S., Iagaru, A.
2021; 11 (6)
- **A Pilot Study of 68Ga-PSMA11 PET/MRI and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer**
Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G., Aparici, C., Moradi, F., Thong, A., Sonn, G., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2021
- **Perfusion Only Scans with and without SPECT/CT in the Era of COVID-19**
Zhang, R., Moradi, F., Aparici, C., Davidzon, G., Nguyen, J., Iagaru, A., Franc, B.
SOC NUCLEAR MEDICINE INC.2021
- **High-specific-activity 131I-MIBG vs 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Jha, A., Taieb, D., Carrasquillo, J. A., Pryma, D. A., Patel, M., Millo, C., de Herder, W. W., Del Rivero, J., Crona, J., Shulkin, B. L., Virgolini, I., Chen, A. P., Mittal, et al
2021
- **Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience**
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., Franc, B., Iagaru, A., Aparici, C.
LIPPINCOTT WILLIAMS & WILKINS.2021: 456-457
- **Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)**
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., Franc, B., Iagaru, A., Aparici, C.

LIPPINCOTT WILLIAMS & WILKINS.2021: 456

- **Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience**
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., Franc, B., Iagaru, A., Aparici, C.
LIPPINCOTT WILLIAMS & WILKINS.2021: 456-457
- **Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience**
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Moradi, F., Nguyen, J., Franc, B., Iagaru, A., Aparici, C.
LIPPINCOTT WILLIAMS & WILKINS.2021: 456
- **Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience**
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Moradi, F., Nguyen, J., Franc, B., Iagaru, A., Aparici, C.
LIPPINCOTT WILLIAMS & WILKINS.2021: 456
- **Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)**
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., Franc, B., Iagaru, A., Aparici, C.
LIPPINCOTT WILLIAMS & WILKINS.2021: 456
- **Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Morris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D. Y., Wong, J. Y., Pantel, A. R., Cho, S. Y., Gage, K. L., Piert, M. R., Iagaru, A., Pollard, et al
2021
- **Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., Iagaru, A., Franc, B. L.
2021
- **The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.** *Molecular imaging and biology*
Nakamoto, R. n., Harrison, C. n., Song, H. n., Guja, K. E., Hatami, N. n., Nguyen, J. n., Moradi, F. n., Franc, B. L., Aparici, C. M., Davidzon, G. n., Iagaru, A. n.
2021
- **Sigma-1 Receptor Changes Observed in Chronic Pelvic Pain Patients: A Pilot PET/MRI Study.** *Frontiers in pain research (Lausanne, Switzerland)*
Yoon, D., Fast, A. M., Cipriano, P., Shen, B., Castillo, J. B., McCurdy, C. R., Mari Aparici, C., Lum, D., Biswal, S.
2021; 2: 711748
- **Neurovascular, muscle, and skin changes on [18F]FDG PET/MRI in complex regional pain syndrome of the foot: A Prospective Clinical Study.** *Pain medicine (Malden, Mass.)*
Yoon, D., Xu, Y., Cipriano, P. W., Alam, I. S., Mari Aparici, C. A., Tawfik, V. L., Curtin, C. M., Carroll, I. R., Biswal, S.
2021
- **Pulmonary large cell neuroendocrine carcinoma (LCNEC) with confirmed liver metastases negative on 18F-FDG and 68Ga-DOTATATE PET.** *Radiology case reports*
Ninatti, G., Duan, H., Ferri, V., Martin, B. A., Aparici, C. M.
2020; 15 (12): 2698–2700
- **Obituary for Sanjiv Sam Gambhir, MD, PhD.** *Clinical nuclear medicine*
Davidzon, G., Franc, B., Mari Aparici, C., Moradi, F., Nguyen, J., Iagaru, A.
2020
- **Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy.** *Molecular imaging and biology*
Nakamoto, R., C Zaba, L., Rosenberg, J., Arani Reddy, S., W Nobashi, T., Ferri, V., Davidzon, G., Mari Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Lewis Franc, B.
2020
- **A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.**
Baratto, L., Song, H., Duan, H., Aparici, C., Davidzon, G., Moradi, F., Srinivas, S., Iagaru, A.
LIPPINCOTT WILLIAMS & WILKINS.2020

- **Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.**
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Franc, B., Moradi, F., Aparici, C., Davidzon, G., Srinivas, S., Iagaru, A.
AMER SOC CLINICAL ONCOLOGY.2020
- **Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors**
Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, C., Iagaru, A., Davidzon, G.
SOC NUCLEAR MEDICINE INC.2020
- **A pilot study of F-18-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic F-18-FDG PET/CT**
Duan, H., Hatami, N., Baratto, L., Davidzon, G., Aparici, C., Gambhir, S., Koglin, N., Witteles, R., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2020
- **Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer**
Baratto, L., Duan, H., Hatami, N., Aparici, C., Davidzon, G., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2020
- **PSMA-and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer**
Baratto, L., Duan, H., Hatami, N., Song, H., Davidzon, G., Franc, B., Aparici, C., Moradi, F., Nguyen, J., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2020
- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy**
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
SOC NUCLEAR MEDICINE INC.2020
- **Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy**
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
SOC NUCLEAR MEDICINE INC.2020
- **Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)**
Duan, H., Girod, B., Ninatti, G., Ferri, V., Kunz, P., Fisher, G., Moradi, F., Davidzon, G., Franc, B., Iagaru, A., Aparici, C.
SOC NUCLEAR MEDICINE INC.2020
- **Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience**
Duan, H., Ninatti, G., Girod, B., Ferri, V., Guja, K., Song, H., Kunz, P., Fisher, G., Iagaru, A., Aparici, C.
SOC NUCLEAR MEDICINE INC.2020
- **INTERIM ANALYSIS RESULTS OF A PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING**
Baratto, L., Song, H., Duan, H., Aparici, C., Hatami, N., Davidzon, G., Moradi, F., Iagaru, A.
LIPPINCOTT WILLIAMS & WILKINS.2020: E1118
- **Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)**
Duan, H., Girod, B., Ninatti, G., Ferri, Kunz, P., Fisher, G., Moradi, F., Davidzon, G., Franc, B., Iagaru, A., Aparici, M. C.
KARGER.2020: 252
- **Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors**
Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, M. C., Iagaru, A., Davidzon, G.
KARGER.2020: 274
- **Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation. *Radiology case reports***
Girod, B. J., Guja, K. E., Davidzon, G., Chan, F., Zucker, E., Franc, B. L., Moradi, F., Iagaru, A., Aparici, C. M.
2020; 15 (2): 117–19
- **Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)**
Duan, H., Ninatti, G., Girod, B., Ferri, V., Kunz, P. L., Fisher, G. A., Moradi, F., Davidzon, G., Franc, B., Iagaru, A., Mari, C.
AMER SOC CLINICAL ONCOLOGY.2020

- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.** *European journal of nuclear medicine and molecular imaging*
Nakamoto, R. n., Zaba, L. C., Rosenberg, J. n., Reddy, S. A., Nobashi, T. W., Davidzon, G. n., Aparici, C. M., Nguyen, J. n., Moradi, F. n., Iagaru, A. n., Franc, B. L.
2020
- **An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT.** *European journal of nuclear medicine and molecular imaging*
Guja, K. E., Brown, R. n., Girod, B. n., Song, H. n., Harrison, C. n., Franc, B. L., Moradi, F. n., Davidzon, G. n., Iagaru, A. n., Aparici, C. M.
2020
- **Preclinical SPECT and SPECT-CT in Oncology.** *Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer*
Franc, B. L., Seo, Y., Flavell, R., Aparici, C. M.
2020; 216: 359–404
- **Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Song, H., Harrison, C., Duan, H., Guja, K., Hatami, N., Franc, B., Moradi, F., Mari Aparici, C., Davidzon, G., Iagaru, A.
2019
- **Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms** *JOURNAL OF NUCLEAR MEDICINE*
Waseem, N., Aparici, C., Kunz, P. L.
2019; 60 (7): 882–91
- **Preliminary Results of a Prospective Study of Ga-68-RM2 PET/MRI for Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging**
Baratto, L., Duan, H., Harrison, C., Hatami, N., Aparici, C., Davidzon, G., Yohannan, T., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2019
- **Prospective evaluation of F-18- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels**
Harrison, C., Song, H., Franc, B. L., Guja, K., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2019
- **Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer**
Duan, H., Song, H., Baratto, L., Khalaf, M., Hatami, N., Franc, B., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2019
- **Comparison of three interpretation criteria of Ga-68-PS A PET based on inter and intra-reader agreement**
Torihara, A., Nobashi, T., Baratto, L., Park, S., Hatami, N., Duan, H., Aparici, C., Davidzon, G., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2019
- **Quantification of uptake in Ga-68-DOTATATE PET: Correlation between standardized uptake values and patient factors**
Moradi, F., Guja, K., Aparici, C., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2019
- **Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer**
Song, H., Harrison, C., Guja, K., Franc, B., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2019
- **State of the Art: Evaluating the Role of Theranostics in G3 Neuroendocrine Neoplasms.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Waseem, N. L., Aparici, C. M., Kunz, P. L.
2019
- **Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Torihara, A. n., Nobashi, T. n., Baratto, L. n., Duan, H. n., Moradi, F. n., Park, S. n., Hatami, N. n., Aparici, C. n., Davidzon, G. n., Iagaru, A. n.
2019

- **Correction: shaped magnetic field pulses by multi-coil repetitive transcranial magnetic stimulation (rTMS) differentially modulate anterior cingulate cortex responses and pain in volunteers and fibromyalgia patients.** *Molecular pain*
Tzabazis, A., Aparici, C. M., Rowbotham, M. C., Schneider, M. B., Etkin, A., Yeomans, D. C.
2014; 10: 16-?
- **Correction: Shaped Magnetic Field Pulses by Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) Differentially Modulate Anterior Cingulate Cortex Responses and Pain in Volunteers and Fibromyalgia Patients.** *Molecular pain*
Tzabazis, A., Aparici, C. M., Rowbotham, M. C., Schneider, M. B., Etkin, A., Yeomans, D. C.
2014; 10: 174480691016
- **Shaped magnetic field pulses by multi-coil repetitive transcranial magnetic stimulation (rTMS) differentially modulate anterior cingulate cortex responses and pain in volunteers and fibromyalgia patients** *MOLECULAR PAIN*
Tzabazis, A., Aparici, C. M., Rowbotham, M. C., Schneider, M. B., Etkin, A., Yeomans, D. C.
2013; 9
- **Steerable Electrical Currents using Multi-coil rTMS: Clinical Effects of Modifying Current Direction**
Schneider, M., Yang, S., Aparici, C., VanBrocklin, H., Seo, Y., Etkin, A., Patrick, K., Yeomans, D. C.
ELSEVIER SCIENCE INC.2012: 282S
- **Pattern of 18F-FDG Uptake in the Spinal Cord in Patients With Non-Central Nervous System Malignancy** *SPINE*
Do, B. H., Mari, C., Tseng, J. R., Quon, A., Rosenberg, J., Biswal, S.
2011; 36 (21): E1395-E1401
- **F-18-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?** *HELLENIC JOURNAL OF NUCLEAR MEDICINE*
Iagaru, A., Wang, Y., Mari, C., Quon, A., Goris, M. L., Horning, S., Gambhir, S. S.
2008; 11 (3): 153-156
- **[Introduction to the molecular imaging].** *Revista espanola de medicina nuclear*
Mari Aparici, C.
2006; 25 (6): 394-409
- **F-18FDG PET evaluation of bronchial plasmacytoma with CT and MRI correlation** *CLINICAL NUCLEAR MEDICINE*
Iagaru, A., Mari, C., Segall, G.
2006; 31 (5): 279-280
- **The role of a positron- and high-energy gamma photon probe in intraoperative localization of recurrent melanoma** *CLINICAL NUCLEAR MEDICINE*
Franc, B. L., Mari, C., Johnson, D., Leong, S. P.
2005; 30 (12): 787-791
- **Bone morphogenetic protein 2 and retinoic acid accelerate in vivo bone formation, osteoclast recruitment, and bone turnover** *TISSUE ENGINEERING*
Cowan, C. M., Aalami, O. O., Shi, Y. Y., Chou, Y. F., Mari, C., Thomas, R., Quarto, N., Nacamuli, R. P., Contag, C. H., Wu, B., Longaker, M. T.
2005; 11 (3-4): 645-658
- **Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor** *JOURNAL OF NUCLEAR MEDICINE*
Blankenberg, F. G., Mandl, S., Cao, Y. A., O'Connell-Rodwell, C., Contag, C., Mari, C., Gaynutdinov, T. I., Vanderheyden, J. L., Backer, M. V., Backer, J. M.
2004; 45 (8): 1373-1380
- **Apoptosis in a rodent model of cranial suture fusion: In situ imaging and gene expression analysis** *PLASTIC AND RECONSTRUCTIVE SURGERY*
Fong, K. D., Song, H. M., Nacamuli, R. P., Franc, B. L., Mari, C., Fang, T. D., Warren, S. M., Contag, C. H., Blankenberg, F. G., Longaker, M. T.
2004; 113 (7): 2037-2047
- **Detection of focal hypoxic-ischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/reperfusion using radiolabeled annexin V** *EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING*
Mari, C., Karabiyikoglu, M., Goris, M. L., Tait, J. F., Yenari, M. A., Blankenberg, F. G.
2004; 31 (5): 733-739
- **Adipose-derived adult stromal cells heal critical-size mouse calvarial defects** *NATURE BIOTECHNOLOGY*
Cowan, C. M., Shi, Y. Y., Aalami, O. O., Chou, Y. F., Mari, C., Thomas, R., Quarto, N., Contag, C. H., Wu, B., Longaker, M. T.
2004; 22 (5): 560-567

- **Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome.** *Molecular imaging*
Mandl, S. J., Mari, C., Edinger, M., Negrin, R. S., Tait, J. F., Contag, C. H., Blankenberg, F. G.
2004; 3 (1): 1-8
- **The use of (99m)Technetium-labeled MCP-1 to assess, graft coronary artery disease in rat cardiac allografts** *JOURNAL OF HEART AND LUNG TRANSPLANTATION*
Kown, M. H., Jahncke, C. L., Lijkwan, M. A., Koransky, M. L., Mari, C., Berry, G. J., Blankenberg, F. G., Strauss, H. W., Robbins, R. C.
2002; 21 (9): 1009-1015
- **Radiotracer characterization of coronary artery lesions** *NUCLEAR MEDICINE COMMUNICATIONS*
Mari, C., Strauss, H. W.
2002; 23 (8): 703-6
- **Zinc chloride-mediated reduction of apoptosis as an adjunct immunosuppressive modality in cardiac transplantation** *JOURNAL OF HEART AND LUNG TRANSPLANTATION*
Kown, M. H., van der Steenhoven, T. J., Jahncke, C. L., Mari, C., Lijkwan, M. A., Koransky, M. L., Blankenberg, F. G., Strauss, H. W., Robbins, R. C.
2002; 21 (3): 360-365
- **Development of radiocontrast agents for vascular imaging: progress to date.** *American journal of cardiovascular drugs*
Blankenberg, F. G., Mari, C., Strauss, H. W.
2002; 2 (6): 357-365